Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease

The introduction of this new therapy has been simple and mostly well tolerated in our sick group of patients. With the usual reservations concerning the open-label nature of our observations, macitentan has good signals regarding oxygen saturations and encouraging signals relating to efficacy.